Arsani William - 13 Aug 2025 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol
DSGN
Transactions as of
13 Aug 2025
Transactions value $
-$2,953,792
Form type
4
Filing time
14 Aug 2025, 16:15:08 UTC
Previous filing
12 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
William Arsani Director C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD /s/ Mustapha Parekh, Attorney-in-Fact 14 Aug 2025 0001848372

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Sale -$1,811,250 -345,000 -12% $5.25 2,655,000 13 Aug 2025 By Logos Global Master Fund LP F1
transaction DSGN Common Stock Sale -$1,142,541 -217,627 -18% $5.25 1,000,000 13 Aug 2025 By Logos Opportunities Fund II LP F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2 Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.